MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Movement Disorder Fellowships: Assessment and Recruitment Strategies to Meet Clinical Needs

    M. Rashid, A. Zafar, J. Owens, G. Patino, M. Robbins, S. Sandrone, H. Sarva (Ottawa Hills, USA)

    Objective: 1. Identify factors leading to lower number of residents interested in movement disorders fellowship. 2. Propose strategies to increase recruitment. Background: The prevalence of…
  • MDS Virtual Congress 2021

    Characteristics and outcomes of Parkinson’s disease individuals hospitalized with COVID-19 in a New York City hospital system

    L. Nwabuobi, C. Zhang, C. Henchcliffe, H. Shah, H. Sarva, A. Lee, H. Kamel (New York, USA)

    Objective: To determine the clinical characteristics and outcomes in hospitalized individuals with Parkinson's disease (PD) infected with COVID-19 Background: The COVID-19 pandemic has caused worse…
  • MDS Virtual Congress 2021

    Evaluation of Care delivery model for integrated care and self-management for people with Parkinson’s disease with Deep Brain Stimulation

    D. Dash, D. Cote, J. Conway, A. Basndwah, D. Grimes, T. Mestre (Ottawa, Canada)

    Objective: To evaluate the implementation and impact potential of a pragmatic network for PD care, the Integrated Parkinson Care Network (IPCN) for patients with chronic…
  • MDS Virtual Congress 2021

    Tele and video consultations of patients with parkinsonism in the Brazilian public health system – a real life feasibility study

    D. Dos Santos, D. Freire Camelo, M. Strelow, M. Silva, P. Führ, L. Marins, A. Schumacher-Schuh (Porto Alegre, Brazil)

    Objective: To evaluate the feasibility and identify obstacles in conducting teleconsultations for patients with parkinsonism in the Brazilian public health system Background: Patients with parkinsonism…
  • MDS Virtual Congress 2021

    Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months

    G. Corcoran, A. Karunakara, B. Vaughn, E. Brand-Schieber, T. Foltynie, R. Barker, S. Palfi (New York, USA)

    Objective: Results from cohort 2 in the Phase 1/2 SUNRISE-PD study (NCT03720418) at 6 months (6M) post administration of AXO-Lenti-PD (ALPD) gene therapy are presented.…
  • MDS Virtual Congress 2021

    Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study

    RM. Hutchison, K. Fraser, M. Yang, B. Hirschhorn, J. Xiao, D. Scott, B. Bedell, K. Evans, D. Graham, L. Martarello, J. Beaver, J. Cedarbaum, T. Fox, A. Siderowf, A. Lang (Cambridge, USA)

    Objective: To evaluate the effects of cinpanemab on biomarkers in participants with Parkinson’s disease (PD). Background: SPARK (NCT03318523) was designed to evaluate the safety, pharmacokinetics,…
  • MDS Virtual Congress 2021

    The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials

    C. Mañeru, S. Meyer (Barcelona, Spain)

    Objective: To identify the areas with specific training needs for Rater Training Programs (RTP) on the Hauser Diary in Parkinson’s disease (PD) clinical trials Background:…
  • MDS Virtual Congress 2021

    Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease

    J. Suescun, M. Schiess, Z. Jiang, V. Thyne, T. Iqbal, N. Utay, M. Newmark, A. Dupont, A. Alexander, H. Dupont (Houston, USA)

    Objective: To evaluate the impact of fecal microbiome transplant (FMT) on disease progression as a secondary outcome of a safety study using PRIM-DJ2727 in Parkinson's…
  • MDS Virtual Congress 2021

    The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial

    V. Dostal, K. Chaudhuri, P. Odin, M. Kurtis, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Norwich, United Kingdom)

    Objective: To assess the tolerability of opicapone (OPC) when used in elderly patients with Parkinson’s disease (PD) in real-world conditions. Background: OPC proved to be…
  • MDS Virtual Congress 2021

    Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…
  • « Previous Page
  • 1
  • …
  • 531
  • 532
  • 533
  • 534
  • 535
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley